» Articles » PMID: 22854645

Summary of the KDIGO Guideline on Anemia and Comment: Reading Between the (guide)line(s)

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 2012 Aug 3
PMID 22854645
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

The kidney disease improving global outcomes (KDIGO) clinical practice guideline for anemia in chronic kidney disease (CKD) is designed to assist health-care providers in treating CKD patients with anemia. A guideline is not intended to define a standard of care, and should not be construed as one, nor should it be interpreted as prescribing an exclusive course of management. It is intended to provide information and to allow the practitioner to make an informed decision, based on evidence and expert judgment. Every health-care professional making use of these recommendations is responsible for evaluating the appropriateness of applying them in any particular clinical situation. Owing to the general nature of a guideline, it is sometimes difficult to translate it to an individual patient's condition. As the primary goal is to improve patient care, we have decided to focus on practical clinical aspects of the KDIGO anemia guideline.

Citing Articles

Prognostic nutritional index as an independent risk factor for disease progression in patients with IgA nephropathy.

Wang S, Zhou H, Dong L, Qin W Front Med (Lausanne). 2025; 12:1530312.

PMID: 40070651 PMC: 11893860. DOI: 10.3389/fmed.2025.1530312.


Safety of High-Dose Intravenous Iron in Hemodialysis Patients: Results from the National Health Insurance Service (2019-2020) in South Korea.

Cho A, Bae Y, Kim M, Kim D, Lee Y, Park H J Clin Med. 2025; 14(1.

PMID: 39797146 PMC: 11721372. DOI: 10.3390/jcm14010063.


Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis.

Garbelli M, Baro Salvador M, Rincon Bello A, Samaniego Toro D, Bellocchio F, Fumagalli L Biomedicines. 2024; 12(10).

PMID: 39457532 PMC: 11504963. DOI: 10.3390/biomedicines12102219.


Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?.

Kanbay M, Copur S, Yilmaz Z, Mallamaci F, Zoccali C J Nephrol. 2024; .

PMID: 39453604 DOI: 10.1007/s40620-024-02117-0.


Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study.

Otsuka E, Kitamura M, Funakoshi S, Mukae H, Nishino T Ren Fail. 2024; 46(2):2410375.

PMID: 39378117 PMC: 11463015. DOI: 10.1080/0886022X.2024.2410375.